Bio-Techne Corp (TECH) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $56.02 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum.
Bio-Techne develops and manufactures life science reagents, instruments, and diagnostic products in two segments: Protein Sciences (~72% of fiscal 2025 net sales) and Diagnostics & Spatial Biology (~28%). Products are sold to pharmaceutical, biotech, academic, and clinical... Read more
Sell if holding. Analyst target reached at $56.02 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum. Chart setup: Death cross but MACD improving, RSI 72. Score 5.1/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.
About Bio-Techne Corp
About Bio-Techne Corp
Bio-Techne's Protein Sciences segment generated approximately 72% of the company's net sales in fiscal 2025, spanning biological reagents, cytokines, antibodies, and automated protein analysis instruments sold under the R&D Systems, Tocris Biosciences, and Novus Biologicals brands. The Diagnostics and Spatial Biology segment contributed the remaining 28%, anchored by spatial genomics tools from Advanced Cell Diagnostics and the Lunaphore acquisition completed at the start of fiscal 2024. Bio-Techne employs approximately 3,100 people globally, about 2,300 of whom are in the United States, and introduced over 400 new products in fiscal 2025.
Bio-Techne earns revenue primarily through direct sales and distribution agreements. In the Protein Sciences segment, the company sells directly to pharmaceutical, biotech, and academic research customers in North America, Europe, and China, with additional distribution through Thermo Fisher Scientific and third-party distributors in Japan, China, and eastern Europe. The Diagnostics and Spatial Biology segment generates revenue from OEM agreements (the majority of Diagnostic Reagents division sales), direct spatial biology instrument and assay sales, and lab-developed test services such as the ExoDx Prostate urine-based assay for prostate cancer detection. Bio-Techne discloses no single end-user customer exceeding 10% of net sales in either segment during fiscal 2025, 2024, or 2023. Approximately 44% of sales revenue in fiscal 2025 came from outside the U.S. Competitive pressure is increasing as pharmaceutical and biotech industry consolidation concentrates purchasing decisions, and manufacturers from Asia have entered certain markets with lower-cost alternatives.
Show full overview
For some laboratory instruments and components requiring specific regulatory qualifications, Bio-Techne may rely on a single supplier or a limited number of suppliers, and the 10-K notes that alternative manufacturing or sourcing is not always available on a timely basis when FDA manufacturing requirements apply. This supply concentration is most visible in instruments and related cartridges. Separately, Bio-Techne plans to acquire the remaining 80.1% stake in Wilson Wolf Corporation by end of calendar 2027, contingent on Wilson Wolf achieving named revenue or EBITDA targets—an obligation the filing estimates could close earlier if milestones are hit, subject to timing uncertainty.
See also: Healthcare · Biotechnology
From Bio-Techne Corp's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Bio-Techne Corp
Latest news
- NEWS Jim Cramer reveals the secret to finding a winning tech stock in this market - CNBC — CNBC positive
- NEWS Tech giants’ results show rosy outlook for AI boom and US stock market - The Guardian — The Guardian positive
- NEWS Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock? - Yahoo Finance — Yahoo Finance neutral
- NEWS Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock? - Zacks Investment Research — Zacks Investment Research neutral
- NEWS Bio-Techne (TECH) Expected to Announce Earnings on Wednesday - MarketBeat — MarketBeat neutral
Generated 2026-06-17T08:56:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-02-11Item 5.02MEDIUMDr. Matt McManus (DSS Segment President) transitioning from role effective March 1, 2026. Steve Crouse appointed as DSS President effective March 1, 2026; currently SVP Analytical Solutions. Successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $56.02 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative momentum. Chart setup: Death cross but MACD improving, RSI 72. Prior stop was $52.10. Score 5.1/10, moderate confidence.
Take-profit target: $55.34 (-1.2% upside). Prior stop was $52.10. Stop-loss: $52.10.
Analyst target reached - limited upside remaining; Negative momentum; Below 200-MA, MA slope -1.1%/30d (confirmed downtrend).
Bio-Techne Corp trades at a P/E of 77.1 (forward 26.3). TrendMatrix value score: 4.3/10. Verdict: Sell.
22 analysts cover TECH with a consensus score of 4.0/5. Average price target: $62.
What does Bio-Techne Corp do?Bio-Techne develops and manufactures life science reagents, instruments, and diagnostic products in two segments:...
Bio-Techne develops and manufactures life science reagents, instruments, and diagnostic products in two segments: Protein Sciences (~72% of fiscal 2025 net sales) and Diagnostics & Spatial Biology (~28%). Products are sold to pharmaceutical, biotech, academic, and clinical customers globally; no single customer exceeded 10% of either segment's net sales.